ACADIA Pharmaceuticals (NASDAQ:ACAD) Rating Lowered to “Hold” at Wall Street Zen

ACADIA Pharmaceuticals (NASDAQ:ACAD) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Wall Street Zen reports.

A number of other equities analysts have also commented on ACAD. Bank of America reaffirmed a “buy” rating and issued a $14.50 price objective on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Morgan Stanley lifted their price objective on shares of ACADIA Pharmaceuticals from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 25th. Citizens Jmp cut their target price on shares of ACADIA Pharmaceuticals from $36.00 to $33.00 and set a “market outperform” rating on the stock in a research note on Friday, September 25th. Stifel Nicolaus increased their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a report on Tuesday, July 21st. Finally, William Blair set a $33.00 target price on ACADIA Pharmaceuticals in a report on Monday, September 28th. Thirteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.45.

ACADIA Pharmaceuticals Trading Down 1.1%

ACAD stock opened at $21.24 on Wednesday. ACADIA Pharmaceuticals has a one year low of $18.39 and a one year high of $30.96. The firm has a market capitalization of $3.66 billion, a PE ratio of 10.07 and a beta of 0.87. The firm has a 50-day moving average of $23.03 and a two-hundred day moving average of $23.62.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.11. ACADIA Pharmaceuticals had a net margin of 30.13% and a return on equity of 9.12%. The business had revenue of $342.30 million for the quarter, compared to the consensus estimate of $332.58 million. During the same period last year, the firm posted $0.42 earnings per share. The firm’s quarterly revenue was up 22.8% compared to the same quarter last year. On average, equities research analysts anticipate that ACADIA Pharmaceuticals will post 0.64 earnings per share for the current year.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark Schneyer sold 3,321 shares of the stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $20.88, for a total value of $69,342.48. Following the completion of the sale, the executive vice president owned 71,322 shares in the company, valued at $1,489,203.36. This represents a 4.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 26.20% of the stock is currently owned by insiders.

Institutional Trading of ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Rice Hall James & Associates LLC acquired a new position in ACADIA Pharmaceuticals during the second quarter worth $15,658,000. State of Wyoming bought a new position in ACADIA Pharmaceuticals during the second quarter valued at about $1,234,000. Bank of America Corp DE boosted its stake in shares of ACADIA Pharmaceuticals by 27.2% during the 1st quarter. Bank of America Corp DE now owns 1,553,770 shares of the biopharmaceutical company’s stock worth $34,587,000 after acquiring an additional 332,325 shares in the last quarter. Virtus Advisers LLC bought a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth about $1,123,000. Finally, GSA Capital Partners LLP bought a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth $1,783,000. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: ACADIA earned $0.31 per share, beating analyst expectations of about $0.20, while revenue of $342.3 million exceeded estimates of $332.6 million and increased 22.8% year over year. The company also cited continued commercial momentum for DAYBUE and NUPLAZID. Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
• Positive Sentiment: RBC noted continued DAYBUE momentum in the quarter, supporting the view that the company’s commercial growth drivers remain active. Acadia Pharmaceuticals Sees Continued Daybue Momentum in Q3, RBC Says
• Negative Sentiment: Wall Street Zen downgraded ACADIA to Hold, a cautious rating change that may have weighed against the strong earnings news. ACADIA Pharmaceuticals Downgraded by Wall Street Zen to Hold

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.